Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Identifying biomarkers and therapeutic targets for COPD

ABSTRACT: Biological indicator and lung proteomics analyses were performed to identify potential therapeutic targets.

ORGANISM(S): Mus Musculus

SUBMITTER: Xishuai Wang

PROVIDER: PXD054322 | iProX | Sat Jul 27 00:00:00 BST 2024

REPOSITORIES: iProX

ACCESS DATA

Json Xml

Similar Datasets

Application of the ISM bioinformatics platform in detection of new therapeutic targets and potential therapeutic molecules

Project description:Application of EIIP / ISM bioinformatics platform in detection of new therapeutic targets and potential therapeutic molecules. Study of the molecular basis of rare human diseases

2020-12-16 | PRJEB42044 | EVA

Identifying Novel Therapeutic Targets by Combining Transcriptional Data with Ordinal Clinical Measurements

Project description:Identifying Novel Therapeutic Targets by Combining Transcriptional Data with Ordinal Clinical Measurements

| PRJNA386152 | ENA

Molecular classification and therapeutic targets in extrahepatic cholangiocarcinoma

Project description:Molecular classification and therapeutic targets in extrahepatic cholangiocarcinoma

| PRJNA547577 | ENA

Supermeres, a new functional extracellular nanoparticle replete with disease biomarkers and therapeutic targets

Project description:Supermeres, a new functional extracellular nanoparticle replete with disease biomarkers and therapeutic targets

| PRJNA707335 | ENA

Supermeres, a new functional extracellular nanoparticle replete with disease biomarkers and therapeutic targets

Project description:Supermeres, a new functional extracellular nanoparticle replete with disease biomarkers and therapeutic targets

| PRJNA707327 | ENA

Functional Proteogenomics Reveals Biomarkers and Therapeutic Targets in Lymphomas

Project description:The proteomic and posttranslational modification signatures of most cancers are unknown. N-linked glycosylation is a post-translational modification that targets proteins for membrane expression or secretion making this class of proteins attractive cancer biomarkers and therapeutic targets. Using an unbiased mass spectrometry (MS)-based approach we generated a compendium of 1,155 N-linked glycoproteins (2,160 N-glycosites) from 44 human primary lymphomas and malignant lymphoma cell lines. Hierarchical clustering highlighted distinct subtype signatures which included several novel subtype-specific biomarkers. Orthogonal immunologic studies in 671 primary lymphoma tissue biopsies, 36 lymphoma-derived cell lines or 8 patient-derived circulating tumor cell samples corroborated MS-based glycoproteomic data and authenticated selected proteins as tissue biomarkers. Functional targeting using a toxin-conjugated ligand in vitro and RNAi-mediated silencing targeting subtype-specific glycoproteins abrogated lymphoma growth in vivo. Our results demonstrate the utility of global N-glycoproteomics discovery of cancer biomarkers and targets for precision therapeutics.

2017-06-19 | PXD003469 | Pride

Potential Therapeutic Targets for Donor Lung Repair During Human Ex Vivo Lung Perfusion Prior to Transplantation

Project description:Potential Therapeutic Targets for Donor Lung Repair During Human Ex Vivo Lung Perfusion Prior to Transplantation

| PRJNA524402 | ENA

Identifying CNS-colonizing T cells as potential therapeutic targets to prevent progression of multiple sclerosis

Project description:Identifying CNS-colonizing T cells as potential therapeutic targets to prevent progression of multiple sclerosis

| PRJNA604770 | ENA

Mutations-Upstream-of-Metabolomic-Signature Based Functional Analyses Identify Prognostic Biomarkers and Therapeutic Targets in Pancreatic Ductal Adenocarcinoma

Project description:<p>Cross-talk among downstream regulatory networks of genome mutations has been the major hypothetical mechanism underlying poor prognosis and low-responsive rates for targeted therapy of pancreatic ductal adenocarcinoma (PDAC). By applying a causal inference-based mutation-upstream-of-the-metabolomic-signature (MUMS), we demonstrated a potential application of prognostic relevant serum metabolomic signature as an indicator to aggregate crosstalk among respective regulatory network downstream of genome mutations, and their collective interference on tumor progression. Moreover, a feature selection of 9-serum metabolites panel also highlights the clinical potential for predicting survival outcomes across multiple PDAC cohorts. Notably, integrating causal inference-based MUMS analysis identified and functional verified GRPEL1 as a novel tumour promoting gene, which shares a common down-stream metabolic signature with mTOR/PI3K/Akt signaling, sensitizing PDAC cells to mTOR inhibition-induced proliferation arrest. Our MUMS based functional cross-talk analysis provided proof-of-concept evidence that serum metabolic signatures reflect crosstalk among tumour mutational landscape, and such co-regulations would provide a novel aspect for identifying neo-targets for targeted therapy and rational based combined therapy design.</p>

2025-10-13 | MTBLS13127 | MetaboLights

Mutations-Upstream-of-Metabolomic-Signature Based Functional Analyses Identify Prognostic Biomarkers and Therapeutic Targets in Pancreatic Ductal Adenocarcinoma

2025-10-13 | MTBLS13116 | MetaboLights